Big Data bring new opportunities to modern society and challenges to data scientists. On the
one hand, Big Data hold great promises for discovering subtle population patterns and …

Although several mechanisms have been proposed to explain the activity of thalidomide,
lenalidomide and pomalidomide in multiple myeloma (MM), including demonstrable anti …

Thalidomide and the immunomodulatory drug, lenalidomide, are therapeutically active in
hematological malignancies. The ubiquitously expressed E3 ligase protein cereblon …

Cereblon (CRBN), a substrate receptor for the cullin-RING ubiquitin ligase 4 (CRL4)
complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of …

Immunomodulatory drugs (IMiDs), such as thalidomide and its derivatives lenalidomide and
pomalidomide, are key treatment modalities for hematologic malignancies, particularly …

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, with a lifetime
risk of 0.49%. 1 It is characterized by the clonal expansion of CD5+ IgD+/IgM+ B …

Thalidomide and its analogues (lenalidomide and pomalidomide) are small molecule
glutamic acid derivatives of the immunomodulatory drug (IMiD) class. In addition to the …

Cereblon (CRBN), originally identified as a gene associated with intellectual disability, was
identified as primary target of thalidomide. Accumulating evidence has shown that CRBN is …

Immunomodulatory drugs (IMiDs), including thalidomide derivatives such as lenalidomide
and pomalidomide, offer therapeutic benefit in several hematopoietic malignancies and …

It has been found that nonsense mutation R419X of cereblon (CRBN) is associated with
autosomal recessive non-syndromic mental retardation. Further experiments showed that …